Recursion Pharmaceuticals

About

Recursion Pharmaceuticals leverages extensive biological and chemical datasets – exceeding 65 petabytes encompassing phenomics, transcriptomics, and patient data – to power its Recursion OS drug discovery platform. This platform utilizes computer vision, machine learning, and a proprietary supercomputer, BioHive-2, to analyze cellular images and predict drug efficacy, significantly accelerating hit identification and IND-enabling studies. Currently, Recursion is advancing a pipeline of potential therapies, including REC-3565 for B-cell lymphomas which is in Phase 1 clinical trials, and has established strategic partnerships with pharmaceutical and technology leaders to expand its AI-driven drug discovery capabilities.

Focus Areas

Technology Focus

Key People